- Home
- NTIP vs TENX Comparison
NTIP vs TENX Comparison
Compare NTIP & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- TENX
- Stock Information
- Founded
- NTIP 1990
- TENX 1967
- Country
- NTIP United States
- TENX United States
- Employees
- NTIP N/A
- TENX N/A
- Industry
- NTIP Multi-Sector Companies
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- TENX Health Care
- Exchange
- NTIP Nasdaq
- TENX Nasdaq
- Market Cap
- NTIP 32.0M
- TENX 27.3M
- IPO Year
- NTIP 1998
- TENX N/A
- Fundamental
- Price
- NTIP $1.60
- TENX $6.28
- Analyst Decision
- NTIP
- TENX Strong Buy
- Analyst Count
- NTIP 0
- TENX 4
- Target Price
- NTIP N/A
- TENX $16.67
- AVG Volume (30 Days)
- NTIP 65.6K
- TENX 47.8K
- Earning Date
- NTIP 10-23-2025
- TENX 11-12-2025
- Dividend Yield
- NTIP 6.25%
- TENX N/A
- EPS Growth
- NTIP N/A
- TENX N/A
- EPS
- NTIP N/A
- TENX N/A
- Revenue
- NTIP $150,000.00
- TENX N/A
- Revenue This Year
- NTIP N/A
- TENX N/A
- Revenue Next Year
- NTIP N/A
- TENX N/A
- P/E Ratio
- NTIP N/A
- TENX N/A
- Revenue Growth
- NTIP N/A
- TENX N/A
- 52 Week Low
- NTIP $1.16
- TENX $3.25
- 52 Week High
- NTIP $1.90
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- NTIP 55.71
- TENX 57.52
- Support Level
- NTIP $1.56
- TENX $6.02
- Resistance Level
- NTIP $1.63
- TENX $6.50
- Average True Range (ATR)
- NTIP 0.08
- TENX 0.16
- MACD
- NTIP -0.01
- TENX 0.02
- Stochastic Oscillator
- NTIP 28.57
- TENX 43.59
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.